Tudor Investment Corp ET AL Grows Position in Alphatec Holdings, Inc. $ATEC

Tudor Investment Corp ET AL boosted its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 608.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 900,491 shares of the medical technology company’s stock after buying an additional 773,367 shares during the period. Tudor Investment Corp ET AL owned approximately 0.61% of Alphatec worth $13,093,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ATEC. Vanguard Group Inc. boosted its stake in Alphatec by 2.4% during the third quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company’s stock worth $99,091,000 after buying an additional 158,295 shares during the period. American Century Companies Inc. raised its stake in shares of Alphatec by 2.6% in the 3rd quarter. American Century Companies Inc. now owns 6,336,491 shares of the medical technology company’s stock valued at $92,133,000 after acquiring an additional 159,330 shares during the period. Next Century Growth Investors LLC raised its stake in shares of Alphatec by 22.8% in the 2nd quarter. Next Century Growth Investors LLC now owns 2,060,735 shares of the medical technology company’s stock valued at $22,874,000 after acquiring an additional 382,057 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Alphatec by 59.0% in the 3rd quarter. Two Sigma Investments LP now owns 1,794,324 shares of the medical technology company’s stock worth $26,089,000 after acquiring an additional 665,634 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Alphatec by 14.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 879,817 shares of the medical technology company’s stock worth $9,766,000 after acquiring an additional 113,963 shares during the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Stock Performance

Shares of ATEC stock opened at $10.83 on Monday. Alphatec Holdings, Inc. has a fifty-two week low of $8.81 and a fifty-two week high of $23.29. The company has a 50 day moving average price of $13.05 and a 200 day moving average price of $16.47. The stock has a market capitalization of $1.64 billion, a P/E ratio of -11.40 and a beta of 1.12. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.28 and a current ratio of 2.06.

Alphatec (NASDAQ:ATEC) last released its earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $212.93 million for the quarter, compared to analyst estimates of $212.67 million. During the same quarter last year, the company earned ($0.23) earnings per share. Alphatec’s quarterly revenue was up 20.4% compared to the same quarter last year. Equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP David Sponsel sold 163,452 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $12.52, for a total value of $2,046,419.04. Following the sale, the executive vice president directly owned 504,932 shares in the company, valued at approximately $6,321,748.64. This trade represents a 24.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Scott Lish sold 260,535 shares of the business’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $12.30, for a total value of $3,204,580.50. Following the transaction, the chief operating officer directly owned 815,704 shares of the company’s stock, valued at $10,033,159.20. The trade was a 24.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 726,972 shares of company stock valued at $9,184,386 in the last three months. 20.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Loop Capital set a $25.00 target price on shares of Alphatec in a report on Wednesday, December 10th. Stifel Nicolaus decreased their price target on Alphatec from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Alphatec in a research report on Friday, March 27th. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, January 31st. Finally, Wells Fargo & Company upgraded Alphatec to a “strong-buy” rating in a report on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.82.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.